Valuation: Lexeo Therapeutics, Inc.

Market Cap 26Cr 23Cr 21Cr 19Cr 36Cr 2.45TCr 36Cr 254.68Cr 101.44Cr 1.28TCr 96Cr 94Cr 4.06TCr P/E 2026 *
-2.57x
P/E 2027 * -2.28x
Enterprise Value 7.91Cr 7.1Cr 6.56Cr 5.94Cr 11Cr 753.29Cr 11Cr 78Cr 31Cr 394.18Cr 30Cr 29Cr 1.25TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lexeo Therapeutics, Inc.

1 day+9.06%
1 week+4.33%
Current month-7.40%
1 month-0.32%
3 months-28.70%
6 months-46.13%
Current year-68.48%
1 week 2.65
Extreme 2.65
3.14
1 month 2.55
Extreme 2.55
3.69
Current year 2.55
Extreme 2.55
10.75
1 year 2.55
Extreme 2.55
10.99
3 years 1.45
Extreme 1.45
22.33
5 years 1.45
Extreme 1.45
22.33
10 years 1.45
Extreme 1.45
22.33
Manager TitleAgeSince
Chief Executive Officer 46 01/01/2020
Director of Finance/CFO 50 15/08/2025
Chief Tech/Sci/R&D Officer 62 20/01/2026
Director TitleAgeSince
Director/Board Member 46 01/01/2020
Chairman 72 01/01/2021
Director/Board Member 61 01/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/26 Free

Chief Operating Officer

54,750 0.0697%
24/09/26 Free

Chief Financial Officer

54,750 0.0697%
24/09/26 Free

Chief Technology Officer

54,750 0.0697%
Change 5-day change 1-year change 3-year change Capi.($)
+9.06%+4.33% - - 26Cr
Average +9.06%
Weighted average by Cap. +9.06%

Financials

2026 *2027 *
Net sales - -
Net income -10Cr -9.31Cr -8.6Cr -7.79Cr -15Cr -987.99Cr -15Cr -102.88Cr -41Cr -516.99Cr -39Cr -38Cr -1.64TCr -13Cr -12Cr -11Cr -9.77Cr -18Cr -1.24TCr -18Cr -128.96Cr -51Cr -648.03Cr -49Cr -48Cr -2.06TCr
Net Debt -18Cr -16Cr -15Cr -13Cr -25Cr -1.69TCr -25Cr -176.24Cr -70Cr -885.61Cr -67Cr -65Cr -2.81TCr -31Cr -27Cr -25Cr -23Cr -43Cr -2.91TCr -43Cr -302.79Cr -120.6Cr -1.52TCr -114.57Cr -112.15Cr -4.83TCr
Projected Income Statement - Annual - Lexeo Therapeutics, Inc.
Logo Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Employees
63
Date Price Change Volume
28/26/28 $3.130 +9.06% 11,98,378
27/26/27 $2.870 +6.30% 26,84,076
26/26/26 $2.700 -3.57% 11,62,581
23/26/23 $2.800 -3.11% 6,19,383
22/26/22 $2.890 -3.67% 4,92,468
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lexeo Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.130USD
Average target price
20.30USD
Spread / Average Target
+548.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lexeo Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. LXEO Stock